Edgewise Gets FDA Orphan, Rare-Pediatric-Disease Designations for Muscular-Dystrophy Program
By Colin Kellaher
Edgewise Therapeutics has won a pair of key U.S. Food & Drug Administration designations for its EDG-5506 muscular-dystrophy program.
The Boulder, Colo., clinical-stage biopharmaceutical company on Thursday said the FDA granted orphan-drug designation to EDG-5506 for the treatment of Duchenne and Becker muscular dystrophy, and rare-pediatric-disease designation for the treatment of Duchenne.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.
The agency awards priority-review vouchers to companies upon approval of drugs that are granted the rare-pediatric-disease designation, and those vouchers can be used to obtain priority review for another drug or sold to other companies.
Edgewise is currently advancing EDG-5506, a small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Duchenne and Becker, in multiple Phase 2 studies.
There are currently no cures for Duchenne or Becker muscular dystrophy, which are neuromuscular genetic diseases.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 30, 2023 08:41 ET (13:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying